Top Markets
Coin of the day
Health-Chem Corporation Health-Chem Corporation

Health-Chem Corporation

HCLC
Classifica tra le azioni #40843
Health-Chem Corporation, operating through its subsidiary, Transderm... Health-Chem Corporation, operating through its subsidiary, Transderm Laboratories Corporation, specializes in the research, development, manufacturing, and commercialization of transdermal drug delivery systems throughout the United States. Among its key products are transdermal nitroglycerin patches, formulated to provide relief for vascular and cardiovascular symptoms linked to angina pectoris (commonly known as chest pain) via skin absorption. The company additionally offers contract research and development services to third-party clients. Health-Chem Corporation employs a multifaceted sales strategy, directly engaging with wholesalers, distributors, prominent retail pharmacy chains, mail-order pharmacies, and group purchasing organizations. Its products also reach the market indirectly through independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit management firms. Founded in 1970, the company's headquarters are situated in Emigsville, Pennsylvania.
Prezzo delle azioni
$0.0001
Ultima sincronizzazione: 2025-01-02
Capitalizzazione di mercato
$73.99K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Health-Chem Corporation (HCLC)

Categoria

Utile per Health-Chem Corporation (HCLC)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Health-Chem Corporation, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Health-Chem Corporation dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
$7.61B -
US
$4.76B -
US
- -
CN
$-252.70M -
US
$1.42B -
US